Literature DB >> 15090713

Abnormal His-Purkinje system conduction leading to complete atrioventricular block in patients with hypertrophic cardiomyopathy: a report of 3 cases.

Oben Doven1, Dilek Cicek, Hasan Pekdemir, Ahmet Camsari, Tuncay Parmaksiz, Gokhan V Cin, Necdet M Akkus.   

Abstract

This case report describes three hypertrophic cardiomyopathy patients with abnormal His-Purkinje conduction and complete atrioventricular block with attacks of syncope and cardiopulmonary arrest. Although arrhythmias are common in hypertrophic cardiomyopathy, complete atrioventricular block is very rare. Prolonged QRS duration and abnormal His-Purkinje system conduction may result in complete atrioventricular block.

Entities:  

Mesh:

Year:  2004        PMID: 15090713     DOI: 10.1536/jhj.45.347

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  4 in total

Review 1.  The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system.

Authors:  Patrick Fitzgerald; Fred Kusumoto
Journal:  J Interv Card Electrophysiol       Date:  2018-08-10       Impact factor: 1.900

2.  Abnormal heart rate regulation in murine hearts with familial hypertrophic cardiomyopathy-related cardiac troponin T mutations.

Authors:  Jesus Jimenez; Jil C Tardiff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-03       Impact factor: 4.733

3.  Long-Term Survival Following Cardiac Arrest Without Implantable Defibrillator Protection in a Hypertrophic Cardiomyopathy Patient.

Authors:  Mustafa Cetin; Ozgul Ucar; Alper Canbay; Zehra Guven Cetin; Hulya Cicekcioglu; Erdem Diker
Journal:  Cardiol Res       Date:  2011-05-20

4.  Electrocardiogram phenotypes in hypertrophic cardiomyopathy caused by distinct mechanisms: apico-basal repolarization gradients vs. Purkinje-myocardial coupling abnormalities.

Authors:  Aurore Lyon; Alfonso Bueno-Orovio; Ernesto Zacur; Rina Ariga; Vicente Grau; Stefan Neubauer; Hugh Watkins; Blanca Rodriguez; Ana Mincholé
Journal:  Europace       Date:  2018-11-01       Impact factor: 5.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.